Abstract: Objective Our research investigate the usefulness of the serum neuron-specific enolase (NSE）as a tumor marker in lung cancer patients. Methods 510 lung cancer patients were involved the study. The serum NSE levels were measured using the Electrochemiluminescence immunoassay. The serum NSE levels and the positive ratio between different groups were analyzed using One-way analysis of variance (ANOVA) test and the Chi-square test, respectively. Results In the 510 lung cancer patients, there were 150 patients with serum NSE positive. According to the histological type of lung cancer, the positive rate was 80.0%（24/30）in the small cell carcinomas (SCLC) and 26.27%（126/462） in the non-small cell carcinomas (NSCLC). The mean levels of NSE in SCLC and NSCLC patients were 45.50±19.61 ng/mL and 13.99±0.52 ng/mL, respectively. The serum levels of NSE in the SCLC patients were significantly higher (P<0.01) than those NSCLC patients. Conclusions The serum NSE level was useful as a tumor marker for Chinese SCLC patients.

Key words: Lung cancer, neuron-specific enolase, small-cell lung cancer, Non-small cell lung cancer, tumor marker

摘要： 目的 研究神经特异性烯醇化酶（neuron-specific enolase,NSE）在肺癌临床病理分类中的诊断作用及其临床意义。方法 510例肺癌患者血清NSE的检测采用全自动电化学发光免疫分析法。检测数据均值比较采用单因素方差分析，率的比较采用卡方检验。结果 510例肺癌患者中共有150例患者血清NSE检测阳性，其中非小细胞肺癌（Non-small cell lung cancer，NSCLC）有126例，占全部NSCLC患者的26.27%（126/462）；小细胞肺癌（small cell lung cancer，SCLC）患者24例，占全部SCLC患者的80.0%（24/30）。SCLC患者的血清NSE检测阳性的比例（80%）与NSCLC患者相比显著增高（卡方检验，x2=10.64，P<0.01）。此外，NSCLC患者血清NSE均值为13.99±0.52 ng/mL；SCLC患者血清NSE均值为45.50±19.61 ng/mL。SCLC患者血清NSE水平显著高于NSCLC患者（单因素方差分析，P<0.01）。结论 NSE的阳性率和血清中的水平与患者的年龄、性别等均无关系，而与肿瘤的病理类型密切有关，即与肺癌是SCLC还是NSCLC有关。NSE 对SCLC患者是一种较好的肿瘤特异性标志物，可以用于肺癌的诊断并指导治疗。

关键词: 癌, 神经特异性烯醇化酶, 小细胞肺癌, 非小细胞肺癌, 肿瘤标志物